Literature DB >> 13697556

The determination of the isoniazid inactivator phenotype.

D A EVANS, P B STOREY, F B WITTSTADT, K A MANLEY.   

Abstract

Entities:  

Keywords:  GENETICS, HUMAN; ISONIAZID/metabolism

Mesh：

Substances：

Year:  1960        PMID： 13697556     DOI： 10.1164/arrd.1960.82.6.853

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN： 0003-0805


× No keyword cloud information.
  8 in total

1.  ENZYMES AND DRUG SENSITIVITY. ACETYLATION POLYMORPHISMS.

Authors:  D A EVANS
Journal:  Proc R Soc Med       Date:  1964-06

2.  The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine.

Authors:  G A Ellard; P T Gammon; S M Wallace
Journal:  Biochem J       Date:  1972-02       Impact factor: 3.857

3.  Formal genetics of isoniazid metabolism in man.

Authors:  L Iselius; D A Evans
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

4.  A correlated study of the cytogenetic effect of Isoniazid (INH) on cell systems of mammals and man conducted by thirteen laboratories. Introductory remarks.

Authors:  G Röhrborn; H G Miltenburger; K L Radenbach
Journal:  Hum Genet       Date:  1978-05-16       Impact factor: 4.132

5.  Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.

Authors:  Shivaani Kummar; Martin E Gutierrez; Lawrence W Anderson; Raymond W Klecker; Alice Chen; Anthony J Murgo; James H Doroshow; Jerry M Collins
Journal:  Cancer Chemother Pharmacol       Date:  2013-08-03       Impact factor: 3.333

6.  NAT2 gene diversity and its evolutionary trajectory in the Americas.

Authors:  R Bisso-Machado; V Ramallo; V R Paixão-Côrtes; V Acuña-Alonzo; D A Demarchi; J R S Sandoval; A A S Granara; F M Salzano; T Hünemeier; M C Bortolini
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

7.  The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype.

Authors:  Jhon D Ruiz; Carmen Martínez; Kristin Anderson; Myron Gross; Nicholas P Lang; Elena García-Martín; José A G Agúndez
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

8.  NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.

Authors:  Junichi Azuma; Masako Ohno; Ryuji Kubota; Soichiro Yokota; Takayuki Nagai; Kazunari Tsuyuguchi; Yasuhisa Okuda; Tetsuya Takashima; Sayaka Kamimura; Yasushi Fujio; Ichiro Kawase
Journal:  Eur J Clin Pharmacol       Date:  2012-11-14       Impact factor: 2.953
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.